Загрузка...
Nivolumab in renal cell carcinoma: latest evidence and clinical potential
Similar to melanoma, renal cell carcinoma (RCC) has been historically considered as an immunogenic tumor, with interleukin 2 (IL-2) and interferon alpha (IFN-α) being the first approved treatments in the 1990s. However, these therapies were effective in only 10–20% of cases and were not well tolerat...
Сохранить в:
| Опубликовано в: : | Ther Adv Med Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5349425/ https://ncbi.nlm.nih.gov/pubmed/28344662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016679942 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|